We constructed a hirudin cDNA cassette, HV-1.1, that and mass spectroscopic analysis revealed the presence of encodes mature hirudin variant-1 fused to the signal pepan extra N-terminal serine residue, indicating aberrant tide of human tissue-type plasminogen activator (t-PA).
Introduction
Autologous venous and prosthetic grafts are widely used as conduits for peripheral and coronary artery bypass surgery. The utility of these conduits is limited, however, by thrombosis and neointimal hyperplasia, both of which may result from generation of thrombin on the luminal graft surface. Thrombin activates platelets and cleaves fibrinogen, leading to thrombosis and vessel occlusion. 1 Thrombin can also contribute to the development of graft neointimal hyperplasia through its action as a smooth muscle cell mitogen, a mediator of inflammation, and an agonist for the release of platelet-derived growth factor. [2] [3] [4] [5] Hirudin, a 65-amino acid protein secreted by the salivary glands of the medicinal leech, is a potent and specific inhibitor of thrombin. 6 By blocking both the catalytic site and the anion-binding exosite of thrombin, hirudin inhibits the interaction of thrombin both with fibrinogen and with thrombin receptors that are present on the surface of platelets and vascular cells. Recent studies, perfor-med in several animal model systems, have demonstrated that systemically administered hirudin can prevent thrombosis and neointimal proliferation after arterial injury. [7] [8] [9] [10] Systemically administered hirudin has also been used in humans as an adjunct to thrombolytic therapy and coronary angioplasty. Although some shortterm benefits of hirudin infusion have been reported, systemic hirudin administration has failed to prevent restenosis and has been associated in some settings with unacceptable bleeding complications. [11] [12] [13] [14] The hemorrhagic complications associated with systemic hirudin administration may preclude the use of doses that are sufficient to achieve local thrombin inhibition at sites of vascular disease.
We have previously demonstrated that adenovirusmediated gene transfer of hirudin in injured rat arteries results in hirudin secretion from the injured artery at a level that is adequate to reduce neointimal formation. 15 Importantly, this effect was achieved without evidence of systemic anticoagulation. Although adenovirus-mediated delivery of hirudin or other potentially therapeutic proteins to the vessel wall is relatively efficient, adenovirusencoded transgene expression is transient and may be associated with a profound local inflammatory response. 16 In addition, the high prevalence of pre-existing immunity to adenovirus in the human population 386 may limit the ability of adenoviral vectors to deliver genetic material in a clinical setting. 17 Retroviral vectors offer a promising alternative to adenoviral vectors for vascular gene therapy. Because retroviral vectors can insert genetic material into target cell genomic DNA, they have the potential to achieve stable long-term transgene expression. Moreover, many retroviral vectors are devoid of open reading frames encoding viral proteins. Elimination of these open reading frames should prevent destructive host inflammatory responses that are directed against foreign proteins expressed from transduced cells. 18 Although achievement of efficient in vivo gene transfer to blood vessels has been a major problem with retroviral vectors, 19, 20 a recent report suggests that significant levels of in vivo retrovirus-mediated gene transfer may now be feasible. 21 Alternatively, vascular endothelial cells transduced ex vivo with retroviral vectors might be introduced into the vasculature by seeding of these cells on to autologous vascular grafts or synthetic prostheses. We and others have demonstrated the feasibility of seeding retrovirally transduced endothelial cells on to prosthetic grafts, endovascular metal stents and native denuded arteries. [22] [23] [24] As initial steps toward achievement of sustained local thrombin inhibition via retroviral transduction of vascular cells, we constructed retroviral vectors expressing hirudin. We used vector backbones with and without internal splice donor and acceptor sites and constructed hirudin cDNA expression cassettes using two different heterologous signal peptide sequences to direct hirudin secretion. Finally, the vectors were tested for their ability to direct the secretion of intact, biologically active hirudin from cultured human endothelial cells.
Results
Quantification of hirudin secretion from endothelial cells transduced with vectors expressing HV-1.1 Hirudin antigen and thrombin inhibitory activity were measured in 72 h collections of conditioned medium harvested from untransduced human umbilical vein endothelial cells (HUVEC) as well as from HUVEC transduced with the retroviral vectors G 1 HV-1.1, G 1 SHV-1.1 ( Figure  1a ), or the control vector G 1 XSVNa (not shown). G 1 XSVNa lacks a hirudin expression cassette but is otherwise identical to G 1 HV-1.1. Both the G 1 HV-1.1 and G 1 SHV-1.1 vectors contain the HV-1.1 hirudin expression cassette, in which a synthetic cDNA for mature hirudin variant 1 is fused to the coding sequence for a human tissue plasminogen activator (t-PA) signal peptide ( Figure 1b) . G 1 HV-1.1-transduced cells secreted 35 ± 2 ng/10 6 cells/24 h of hirudin antigen, which was associated with a low level of thrombin inhibitory activity (Table  1) . Secretion of hirudin antigen from G 1 SHV-1.1-transduced HUVEC was somewhat lower, demonstrating that the existence of splice donor and acceptor sites in this construct did not increase protein expression levels. Thrombin inhibitory activity in the supernatant of G 1 SHV-1.1-transduced cells did not differ significantly from controls.
Western blot analysis
Recombinant hirudin (recHV-1.1) samples purified from the conditioned medium of G 1 SHV-1.1-transduced cells were analyzed by Western blotting (Figure 2 ). Native hirudin can exist as oligomers at neutral pH; 25 therefore, we anticipated that several species would be identified by the polyclonal anti-hirudin antibody. Several bands were indeed present, with molecular masses corresponding to those of hirudin trimers, dimers and monomers. The pattern of bands detected in the lanes containing recHV-1.1 purified from the conditioned media of retrovirus-transduced cells was similar to that present in lanes containing either native leech hirudin or recombinant hirudin produced in yeast. 
Thrombin gel shift Western blot analysis
To characterize the ability of recHV-1.1 to bind thrombin, purified samples from the conditioned media of G 1 SHV-1.1-transduced cells were incubated with purified human thrombin for 5-10 min at room temperature then subjected to native gel electrophoresis. During native gel electrophoresis proteins migrate according to both charge and mass, permitting differentiation of free thrombin from thrombin complexed to hirudin. Thrombin is a neutrally charged molecule, with a major pI of 7.2-7.6.
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Hirudin has a strong negative charge (pI = 3.8-4.0); thus, the thrombin-hirudin complex (which has an intermediate pI of approximately 5) 27 migrates faster than free thrombin. RecHV-1.1 purified from the conditioned media of retrovirus-transduced cells bound and shifted thrombin in a fashion identical to that of native leech hirudin ( Figure 3 ).
Biochemical and physical properties of recombinant hirudin
To complete the characterization of recombinant hirudin, we measured the specific activity and performed N-terminal amino acid sequence analysis and laser desorption mass spectroscopy on hirudin samples purified from the conditioned medium of retrovirus-transduced cells (Table 2) . Values were compared with those obtained in Because of the aberrant cleavage of the signal peptide and the associated loss of antithrombin activity, we constructed a second cDNA cassette (HV-1.2). This construct contained a cDNA for mature hirudin variant-1 fused to the human growth hormone (hGH) signal peptide. The G 1 HV-1.2 retroviral vector was generated as previously described. Recombinant hirudin (recHV-1.2) purified from the conditioned media of G 1 HV-1.2-transduced cells had a specific activity of 13.5 ± 0.4 ATU/g, similar to that of native leech hirudin and recombinant hirudin produced in yeast. N-terminal amino acid analysis revealed appropriate cleavage of the heterologous hGH signal peptide between Ala −1 and Val +1 (Figure 4 ). Mass spectroscopy of retrovirus-generated recHV-1.2 revealed a protein of 6969.9 AMU, which is within the range of experimental error for a hirudin variant-1 molecule lacking sulfation at Tyr +63 (average theoretical mass 6963.5 AMU).
HUVEC transduced with G 1 HV-1.2 secreted 25 ± 1 ng of hirudin/10 6 cells/24h. Media from G 1 HV-1.2-transduced cells contained significant thrombin inhibitory activity ( Table 1) . Secretion of hirudin by transduced HUVEC was stable for at least 7 weeks after transduction, then declined ( Figure 5) . Notably, at later time-points (beyond 50 days), the general appearance of both transduced and untransduced HUVEC was poor (ie large, vacuolated cells), and the cells no longer grew to confluence. The decline in hirudin expression may thus be due to cellular senescence.
Discussion
Direct thrombin inhibitors have considerable promise as cardiovascular therapeutic agents. Direct thrombin inhibition inhibits thrombosis and decreases vascular lesion formation in animal models. [8] [9] [10] 28 Thrombin inhibition potentiates thrombolysis and improves vessel patency in humans. 29, 30 To develop further the therapeutic potential of direct thrombin inhibition, we have sought to generate viral vectors that can overexpress hirudin from vascular cells. 15 In the present study we constructed and tested several retroviral vectors that express hirudin. The major findings of this study were: (1) retroviral vectors can mediate the expression of biologically active hirudin from human vascular endothelial cells; (2) retroviral transduction results in hirudin secretion that is stable for at least 7 weeks; and (3) heterologous signal peptides in retroviral vectors may be cleaved at unexpected sites.
The endogenous leech signal sequences that direct the secretion of native hirudins have never been reported. Therefore, to achieve secretion of hirudin it was necessary to select a heterologous signal peptide and fuse the coding sequence for this peptide to the coding sequence for mature hirudin. Recombinant hirudin has been expressed previously in prokaryotes and lower eukaryotes, including E. coli, yeast and insect cells (using a baculovirus vector). [31] [32] [33] In each of these systems, hirudin secretion was directed by heterologous signal peptides already known to function efficiently in these species. Because our goal was to express hirudin in a mammalian cell and because there is evidence that use of host cell species-specific signal peptides can result in enhanced secretion and more reliable post-translational processing, 34, 35 we initially used the human t-PA signal peptide to direct hirudin secretion from human endothelial cells. The t-PA signal peptide functions well in human endothelial cells 36 and has also been used successfully as a heterologous signal peptide in other systems. [37] [38] [39] Surprisingly, our efforts to express recombinant hirudin using the t-PA signal peptide yielded a hirudin molecule (recHV-1.1)with an additional N-terminal serine residue. Examination of the t-PA signal peptide sequence suggested strongly that the presence of this serine was due to aberrant signal peptide cleavage. This observed cleavage (between Pro −2 and Ser ) was surprising because cleavage at this site violated the '−3, −1 rule' of von Heijne 40 which predicted the site of signal peptide cleavage to be between Ser −1 and Val +1 . The aberrant cleavage may have been due to the absence of the 9-amino acid t-PA propeptide, which is immediately downstream of the signal peptide in the native t-PA precursor molecule. At least two published studies have reported aberrant N-terminal cleavage consequent to deletion of propeptide sequences in mutant precursor proteins. 41, 42 Consistent with this view, recombinant hirudin that we expressed using the hGH signal peptide (recHV-1.2) was cleaved as predicted between Ala −1 and Val
+1
. The hGH precursor protein does not contain a propeptide sequence; 43 therefore, aberrant cleavage may be less likely when the hGH signal sequence is used to direct heterologous protein secretion.
Because the physical properties of hirudin can be dramatically affected by N-terminal amino acid additions, the aberrant cleavage of the heterologous t-PA signal peptide is likely responsible for the decreased specific activity of recHV-1.1. For example, experimental addition of a glycine or methionine residue to the N-terminus of hirudin increases the thrombin inhibition constant (K i ) of hirudin significantly, 44 although thrombin binding is still of high affinity (K i = 0.5-5.4 nm). The modestly decreased specific activity of recHV-1.1, approximately 60% that of recHV-1.2, is therefore consistent with what would be predicted to result from the addition of an N-terminal serine residue to the hirudin molecule. An appreciation of the biochemical complexities involved in heterologous signal peptide processing is clearly essential in the design of hybrid expression cassettes for gene transfer and gene therapy experiments.
Retrovirus-transduced HUVEC expressed approximately 20-35 ng/10 6 cells/24 h of hirudin. This level of hirudin secretion is similar, on a molar basis, to levels of secretion of other proteins that have been expressed from endothelial cells by retroviral gene transfer. 23, 45 This comparison suggests that our efforts to optimize hirudin expression by using the viral LTR promoter and selecting transduced cells in G418 were reasonably successful. However, this rate of hirudin secretion is approximately one order of magnitude below the rate of hirudin secretion we achieved using an adenoviral vector to express hirudin from HUVEC. 15 Thus, endothelial cells appear capable of producing and secreting a higher amount of hirudin than was achieved in the present study. Although differences in the promoters used in these two vector systems preclude firm conclusions, the superior performance of the adenoviral vector is likely due to the ability of this vector to transfer multiple transgene copies to target cells, 46 whereas our current protocols for retroviral gene transfer achieve delivery of only approximately one transgene copy per cell. 47 This limitation of retroviral gene transfer might be overcome by use of newer generation retroviral vectors, which can be concentrated to higher titers and can effect delivery of multiple transgene copies per cell (up to [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] even in the absence of antibiotic selection, (Ref. 48 , and Dr D Ory, personal communication). Use of these vectors might permit stable secretion of far higher levels of hirudin than are reported here. It is unclear what level of hirudin secretion will be required in order to achieve a therapeutic effect in humans, and therefore we remain uncertain as to whether retroviral vector-mediated expression of hirudin will be clinically useful. However, preliminary in vivo data generated with implanted, G 1 HV1.2-transduced baboon endothelial cells suggest that levels of hirudin secretion that are attainable with current vectors may be adequate to inhibit both thrombosis and intimal hyperplasia. 49 Higher levels of hirudin production may be even more effective.
We previously reported results of in vitro and in vivo investigations testing the hypothesis that seeding smalldiameter prosthetic grafts with endothelial cells modified by a retroviral vector to secrete t-PA would inhibit graft thrombosis. [50] [51] [52] [53] [54] Although the transduced cells secreted t-PA at physiologically meaningful levels, their adherence to graft surfaces under flow conditions was significantly decreased. Because adherence of the t-PA-transduced cells was improved in the presence of aprotinin, the poor adherence of t-PA-transduced cells was likely due to enhanced plasmin-mediated cleavage of extracellular matrix and adhesion proteins. Expression of a therapeutic agent (such as hirudin) that lacks proteolytic activity could represent a superior approach to graft seeding, as hirudin-expressing cells have no apparent predisposition to enhanced proteolysis; these cells could inhibit coagulation without promoting degradation of their underlying matrix.
Local thrombin inhibition, mediated by hirudin-transduced endothelial cells, may eventually be useful not only in improving the performance of synthetic vascular grafts, but also in preventing thrombosis and stenosis of native arteries and in preventing pulmonary thromboembolic disease. Further in vivo studies are now required to investigate the therapeutic potential of retrovirus-transduced endothelial cells secreting hirudin.
Materials and methods
Construction of hirudin cDNA cassettes A cDNA cassette, termed HV-1.1 (Figure 1b) , coding for mature hirudin variant-1 (HV-1) fused to the human t-PA signal peptide and flanked by convenient restriction sites, was constructed by a polymerase chain reaction (PCR)-based technique. The human t-PA signal sequence was chosen as t-PA is a secreted product of human endothelial cells. Because of potential ambiguities regarding the cleavage site of the t-PA propeptide sequence, 55 we included only the signal or 'pre' peptide coding sequence in the construct. Rules of signal peptide cleavage predicted that this 'pre' peptide would be cleaved immediately N-terminal to the Val +1 residue of mature HV-1.
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In the first PCR step, the two halves of the cassette, designated HV-1.1A (5Ј end) and HV-1.1B (3Ј end), were synthesized by seven cycles of PCR (denature, 94°C for 1 min; anneal, 50°C for 2 min; extend, 72°C for 2 min) performed on two pairs of overlapping oligonucleotides. HV-1.1A was synthesized from two 100-base oligonucleotides: Sense: 5Ј CCGGAATTCC GGGCAGCGGC CGC ATCATGG ATGCAATGAA GAGAGGGCTC TGCTGTG TGC TGCTGCTGTG TGGAGCAGTC TTCGTTTCGC CCAGCGTTGT 3Ј. Antisense: 5Ј GCGGATGCAT TTGTTGCCCT GGCCGCAAAC GTTAGAGCCT TCGC ACAGGC ACAGGTTCTG ACCGGATTCA GTGCAGT CAG TGTAAACAAC GCTGGGCGAA 3Ј. HV-1.1B was synthesized from two 75-base oligonucleotides: Sense: 5Ј TCCTGGGCTC TGACGGCGAA AAAAACCAGT GCGT TACTGG CGAAGGTACC CCGAAACCGC AGTCTC 3Ј.
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Antisense: 5Ј CGCTCTAGAG CTATTACTGC AGGT ATTCTT CCGGGATTTC TTCGAAGTCG CCGTCG TTGT GAGACTGCGG TTTCG 3Ј. In the second PCR step, the HV-1.1A and HV-1.1B synthesis products were amplified by 35 cycles of PCR (denature, 94°C for 1 min; anneal, 50°C for 2 min; extend, 72°C for 2 min) using 5Ј and 3Ј flanking oligonucleotides. The flanking primers used for HV-1.1A amplification were as follows: Sense: 5Ј CCGGAATTCCGGGCA 3Ј. Antisense: 5Ј GCGGAT GCATTTGTT 3Ј. The flanking primers for the HV-1.1B amplification were: Sense: 5Ј TCCTGGGCTCTGACG 3Ј. Antisense: 5Ј CGCTCTAGAGCTATT 3Ј. The HV-1.1A and HV-1.1B amplification products were gel purified, digested with NsiI and ligated. The crude ligation products were used as templates to selectively amplify the full-length HV-1.1 cDNA cassette by 35 cycles of PCR (denature, 94°C for 1 min; anneal, 50°C for 2 min; extend, 72°C for 2 min) using the following flanking primers: Sense: 5Ј CCGGAATTCCGGGCA 3Ј. Antisense: 5Ј CGCTCTAGAGCTATT 3Ј. Following gel purification the amplified HV-1.1 cDNA was digested with EcoRI and XbaI and ligated into pBluescript IISK + cloning vector (Stratagene Cloning Systems, La Jolla, CA, USA) to generate pBSHV-1.1.
Due to experimentally determined aberrant cleavage of the HV-1.1 heterologous t-PA signal peptide (see above), a second cDNA cassette termed HV-1.2 ( Figure 1b ) was constructed by a PCR-based method described previously. 15 
Construction of retroviral vectors
The parent vector plasmid pG 1 Figure 1a ) amphotropic retroviral vectors were generated by transfection of vector plasmids into a coculture of GP+E86 58 and PA317 59 packaging cell lines. The titers of clonal retroviral stocks used in these experiments were typically greater than 1 × 10 5 G418-resistant colonies per milliliter.
Cell culture and viral transduction
Characterized human umbilical vein endothelial cells (HUVEC) from a single donor (Clonetics, San Diego, CA, USA; passages 2-10) were maintained at 37°C under 5% CO 2 in complete EGM medium (Clonetics) containing 2% fetal calf serum (FCS). For retroviral transductions, subconfluent HUVEC in 35-mm wells were incubated with 1.5 ml of viral supernatant containing 8 g/ml polybrene (Aldrich Chemical, Milwaukee, WI, USA) for 6 h. Two days later cells were placed into selection with complete medium containing 0.05 mg/ml G418 (Life Technologies, Gaithersburg, MD, USA) for a period of at least 14 days before being used in experiments. This concentration of G418 killed 100% of untransduced cells within 10-14 days.
Recombinant hirudin expression
Hirudin antigen was detected in cell-culture supernatants by ELISA (Imubind Hirudin ELISA; American Diagnostica, Greenwich, CT, USA). The limit of detection was routinely less than 0.2 ng/ml. Thrombin inhibitory activity in cell-culture supernatants was measured by a chromogenic substrate assay 60 with the following modifications: 100 l of culture supernatant were added to 500 l test reagent containing 0.0625-0.125 NIH U/ml human ␣-thrombin (Boehringer Mannheim, Indianapolis, IN, USA), 200 mm Tris-HCl, pH 8.1, 840 mm urea, 25 mm sodium chloride, 75 KIU/ml aprotinin (Boehringer) and 100 ng/ml polybrene (Aldrich). The mixture was incubated for 3-5 min at room temperature after which 200 l were added to 25 l of 2 mm D-phe-pip-arg-pNA (S-2238; KabiVitrum, Stockholm, Sweden). The absorbance at 405 nm was followed for 2 min using a Vmax Kinetic microplate reader (Molecular Devices, Menlo Park, CA, USA) and a Vmax (mOD/min) was measured. The thrombin inhibitory activity, in antithrombin units per milliliter (ATU/ml), was calculated by comparison to native hirudin variant-1 standards (native hirudin; American Diagnostica). All samples were within the linear range of the standard curve (0.031-0.5 ATU/ml). Because the presence of heparin might confound interpretation of the thrombin inhibition assay, heparin was omitted from the culture medium that was used for these studies.
Purification of recombinant hirudin
Recombinant hirudin was purified from media conditioned by PA317 retroviral producer cells transduced with either pG 1 SHV-1.1 or pG 1 HV-1.2. After collection, conditioned medium was centrifuged at 1000 g for 5 min to remove cellular debris and frozen at −20°C until use. Hirudin was purified from conditioned medium in a twostep procedure. In the first step, culture supernatants were applied to an A-25 DEAE Sephadex ion-exchange column (Pharmacia LKB Biotechnology, Uppsala, Sweden) equilibrated with 0.1 m ammonium acetate and 0.1 m sodium chloride, pH 6.0. Recombinant hirudin was eluted by a linear salt gradient 0.1-0.4 m sodium chloride, 0.1 m ammonium acetate, pH 6.0. Fractions containing hirudin antigen were pooled and further purified by FPLC (Pharmacia). Samples were loaded on to a ProRPC HR 5/10 reversed phase column equilibrated with solvent A (0.1% triflouroacetic acid, water). Elution was performed with a 0-50% gradient of solvent B (0.1% triflouroacetic acid, acetonitrile) at 1 ml/min over 30 min. Fractions were assayed for hirudin antigen, pooled, and concentrated by partial lyophilization before further analysis.
Western blot analysis
Samples were electrophoresed through a 15% SDS-polyacrylamide gel using a Tricine SDS running buffer (Novel, San Diego, CA, USA) essentially as described. 61 Samples were boiled for 5 min in loading buffer containing 0.1 m dithiothreitol before electrophoresis. Proteins were transferred to pre-wetted Immobilon-P membranes (Millipore, Bedford, MA, USA) using Towbin buffer 62 without methanol in a Trans-Blot Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, CA, USA) according to the manufacturer's instructions. Pre-stained protein molecular weight standards (Life Technologies) were used to estimate molecular weights and to assess transfer efficiency. After blocking overnight at 4°C with non-fat dry milk, membranes were incubated for 1 h in blocking solution (Life Technologies) containing 1.0 g/ml polyclonal rabbit anti-hirudin IgG antibody (5401; American Diagnostica) which recognizes the carboxyl termini of several hirudin species. Membranes were washed in Tris-buffered saline with 0.5% Tween 20 (TBST) and incubated for 1 h in blocking solution containing 1/4500 dilution of goat anti-rabbit biotinylated antibody (Life Technologies). Following washing, membranes were incubated for 30 min in TBST containing 1/2000 dilution of streptavidin-horseradish peroxidase conjugate (Life Technologies). After extensive washing with TBST, hirudin species were detected by enhanced chemiluminescence (ECL Western Blotting Detection Reagents; Amersham International, Amersham, UK) according to the manufacturer's instruction.
Thrombin gel shift Western blot analysis
Human ␣-thrombin (Boehringer) was incubated at room temperature for 5-10 min with either commercially available native leech hirudin (American Diagnostica) or purified recombinant hirudin from the conditioned medium of G 1 SHV-1.1-transduced PA317 producer cells. Mixtures were electrophoresed through a 7.5% native polyacrylamide gel and proteins were transferred to an Immobilon-P membrane as described above. After blocking, membranes were incubated for 1 h in blocking solution containing 1.0 g/ml polyclonal rabbit IgG directed against human thrombin (4702; American Diagnostica). The bound rabbit IgG was detected with biotinylated goat anti-rabbit IgG, as described above.
Specific activity determination of purified hirudin
The activity of purified hirudin was determined by a thrombin inhibition assay using S-2238 (Chromogenix, Mö lndal, Sweden). Purified hirudin (50 l of an approximately 200 ng/ml solution were added to 850 l of 150 mm Tris-HCl, pH 8.3, and 50 l of 4 NIH U/ml human ␣-thrombin (American Diagnostica) in 150 mm Tris-HCl, pH 8.3, with 1 mg/ml protease-free bovine serum albumin (Boehringer). After equilibration at 37°C for 3-5 min, 50 l of 2 mm S-2238 were added and incubated at 37°C for 2 min. The reaction was stopped by the addition of 100 l of 50% acetic acid, and the absorbance at 405 nm was measured in a 1-ml cuvette. Absorbance was subtracted from values obtained with thrombin-only controls and this value was converted to ATU using 1.25 A 405 /min/ATU. 63 The amount of purified hirudin was determined by ELISA.
Molecular mass and N-terminal sequence determinations
The molecular mass of hirudin species was determined by matrix-assisted laser desorption mass spectroscopy using a Kompact MALDI III mass spectrometer (Kratos Analytical, Manchester, UK) and 3,5-dimethoxy-4-hydroxycinnamic acid (Aldrich) as matrix according to the manufacturer's instruction. N-terminal amino acid sequence analysis was performed by William S Lane of the Harvard Microchemistry Facility (Cambridge, MA, USA). Samples were analyzed by automated Edman degradation using an Applied Biosystems Model 477A Protein Sequencer equipped with an on-line 120 PTH analyzer.
